Beinaglutide

Source high-purity Beinaglutide, a novel long-acting GLP-1 receptor agonist peptide designed for advanced metabolic research. This innovative fusion protein offers extended half-life and potent glucose-dependent insulin secretion, making it ideal for studying type 2 diabetes mechanisms and obesity pathways. Perfect for laboratories investigating incretin therapy and metabolic regulation. High-quality raw material. Get a quote today!

Product Specification

• Product Name: Beinaglutide (Research Grade)
• Appearance: White to off-white lyophilized powder
• CAS No.: Not publicly assigned (Proprietary recombinant fusion protein; often referenced by development code HEC001 or similar)
• Molecular Formula: N/A (Complex recombinant protein; Approx. MW: ~60-70 kDa depending on linker and albumin variant)
• Specification: Purity ≥95% (SDS-PAGE/HPLC); Endotoxin <1.0 EU/mg; Solubility: Soluble in sterile PBS or water
• Ingredient Information: Recombinant human GLP-1 analog fused with human serum albumin (HSA) via a flexible linker; Expressed in CHO or yeast cells

Product Description

Beinaglutide is a next-generation long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, engineered through the fusion of a GLP-1 analog with human serum albumin. This unique structure significantly extends its plasma half-life compared to native GLP-1, allowing for less frequent dosing in therapeutic contexts. It mimics the physiological effects of endogenous GLP-1, including glucose-dependent insulin secretion, suppression of glucagon release, and delay of gastric emptying. In research, Beinaglutide is valued for its potent efficacy in lowering blood glucose levels and promoting weight loss in preclinical models. Its stable profile and strong receptor affinity make it a critical tool for investigating novel treatments for type 2 diabetes, obesity, and related metabolic disorders, offering insights into the potential of albumin-fusion technology in peptide therapeutics.

Product Uses

This ingredient is strictly intended for laboratory research and preclinical studies. It is widely used in metabolic disease research to investigate the mechanisms of GLP-1 receptor activation and its downstream effects on glucose homeostasis. Scientists utilize Beinaglutide in animal models of type 2 diabetes and diet-induced obesity to evaluate efficacy in glycemic control, weight reduction, and lipid metabolism improvement. Additionally, it serves as a key reagent in cell-based assays using pancreatic beta-cell lines to study insulin secretion dynamics and cell proliferation. It is also employed in pharmacokinetic studies to assess the benefits of albumin fusion on peptide stability and circulation time. It is not approved for human consumption or clinical use outside of regulated trials.

Formulation Recommendation

Reconstitution: Dissolve in sterile deionized water or PBS to create a stock solution (e.g., 1–5 mg/mL). Gentle vortexing is recommended to ensure complete solubilization. Aliquot and store at -80°C.
Usage Concentration: In vivo, typical dosing in rodent models ranges from 0.1–10 nmol/kg, administered subcutaneously or intraperitoneally, depending on the study duration and endpoint. In vitro, use concentrations of 1–100 nM for cell culture assays.
Compatibility: Compatible with standard physiological buffers. Avoid repeated freeze-thaw cycles. For stability, store lyophilized powder at -20°C or below. Synergizes well with other metabolic modulators like SGLT2 inhibitors in combination therapy studies, though careful dosing is required to avoid hypoglycemia in animal models.